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Background: Recent studies indicate a central role for the IL-23/IL-17 axis in the pathogenesis of lupus nephritis
(LN) but the importance in the context of treatment outcome is unknown. We studied various cytokines, including
the IL-23/IL-17 axis, in association to histopathology and response to therapy.
Methods: Fifty-two patients with active LN were included. Renal biopsies were performed at baseline and after
immunosuppressive treatment. Serum levels of TNF-α, IFN-γ, IL-6, IL-10, IL-17, IL-23 and TGF-β were analysed at both
biopsy occasions and in 13 healthy controls. IL-17 expression in renal tissue was assessed by immunohistochemistry.
Biopsies were evaluated regarding WHO-classification and renal disease activity was estimated using the BILAG-index.
Improvement of 2 grades in renal BILAG was regarded complete response, and 1 grade partial response.
Results: At baseline, all patients had high disease activity (BILAG A/B). Baseline levels of IL-6, IL-10, IL-17, IL-23 (p < 0.001)
and IFN-γ (p = 0.03) were increased in patients vs. controls. In contrast, TGF-β was lower in patients compared to controls
(p < 0.001).
Baseline levels of IL-17 were higher in patients with persisting active nephritis (WHO III, IV, V) after treatment, i.e. a poor
histological response, vs. WHO I-II (p < 0.03). At follow-up, IL-23 were higher in BILAG-non-responders vs. responders
(p < 0.05). Immunostaining of renal tissue revealed IL-17 expression in inflammatory infiltrates.
Conclusions: High baseline IL-17 predicted an unfavourable histopathological response, and BILAG-non-responders had
high IL-23, indicating that that a subset of LN-patients has a Th-17 phenotype that may influence response to treatment
and could be evaluated as a biomarker for poor therapeutic response.Background
Lupus nephritis (LN) is a severe manifestation of sys-
temic lupus erythematosus (SLE), affecting up to 60% of
SLE patients at some point of the disease [1]. The patho-
genesis for LN is complex and involves multiple compo-
nents of both the innate and adaptive immune systems.
Although the exact mechanisms remain unclear, the
hallmark in the pathogenesis is production of autoanti-
bodies and immune complex formation with subsequent
infiltration by inflammatory cells in renal tissue [2-4].
Many cytokines are also involved and contribute to both
onset and progression of renal pathology.
Interferon (IFN)-α is regarded an important cytokine
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unless otherwise stated.have been put forward in this context, including inter-
leukin (IL)-6, IL-1, tumour necrosis factor (TNF)-α,
IFN-γ, IL-12, IL-10, transforming growth factor (TGF)-β,
IL-2 and more recently the IL-23/IL-17 axis [5-7].
Current studies indicate a central role for IL-17 in the
pathogenesis of LN [8,9]. IL-17 is the main cytokine
from Th17 cells, a T-cell subset evolved from CD4+ T-
cells under the influence of IL-6, IL-21 and IL-1. It is
also produced by other cells, such as T-cell receptor
(TCR)γδ and TCRαβ double negative (DN) T-cells
(CD3 + CD4-CD8-) [9]. IL-17 has strong proinflamma-
tory effects [10], induces other cytokines, promotes re-
cruitment of inflammatory cells and facilitates T-cell
infiltration [9]. A synergy between IL-17 and B-cell acti-
vating factor (BAFF) in promoting B-cell proliferation
and antibody production has also been shown [11]. In-
creased number of Th17 cells as well as high serum
levels of IL-17 has been demonstrated in lupus patientsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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interstitial infiltrating T-cells [15-17].
IL-23 is released from antigen presenting cells and in-
duces expansion of Th17 cells and is necessary for their
maintenance [18], thus forming the IL-23/IL-17 axis.
Previous studies found high serum levels of IL-23 in LN
[13,17] and an expansion of T-cells expressing both high
IL-17 and IL-23-receptor have been demonstrated in
lupus-prone mice [8]. IL-23–treated lymphocytes have
been shown to induce nephritis in mice [8] while IL-23-
receptor deficiency has been found to prevent develop-
ment of nephritis in murine lupus models [19].
Although evidence of the role for Th17 is accumulat-
ing, this has not been put in the context of response to
immunosuppressive treatment in LN patients. Increased
knowledge of cytokines in LN may contribute to further
understanding of the pathogenesis and may lead to iden-
tification of new biomarkers for disease activity and to
the development of new treatment strategies. Here we
studied serum levels of several cytokines, including the
role of Th17 cytokines, in both active disease and after
immunosuppressive therapy in association to histo-
pathological findings and response to therapy. We also
performed tissue stainings for IL-17 in kidney biopsies
from six LN patients.
Methods
Patients
Fifty-two patients with SLE and biopsy-proven active LN
between1996 and 2009 were included. All patients ful-
filled the updated revised American College of Rheuma-
tology (ACR) classification criteria for SLE [20]. As part
of the clinical routine at our unit, all patients underwent
a second renal biopsy following immunosuppressive in-
duction therapy after a median time of 7 months (range
5–15). Clinical data, blood and urinary samples were
collected at both biopsy occasions. Serum samples were
stored at −70°C. Thirteen healthy blood donors, 11 fe-
males and 2 males mean age 36 years (range 18–60),
were used as control group for the cytokine analyses.
Written informed consent was obtained from all subjects
and the study protocol was approved by the regional
ethics committee in Stockholm (KI Forskningsetikkom-
mitte Nord, Karolinska sjukhuset; Regionala etikpröv-
ningsnämnden i Stockholm).
Evaluation of renal function, histopathology and renal
activity
Renal evaluation at the time of both biopsies included
urine analyses (dipslide procedure) and investigation of
24-hour urine albumin excretion. Renal function was de-
termined by serum creatinine levels (μmol/l).
Renal biopsies were evaluated by light microscopy,
immunofluorescence and electron microscopy and weregraded according to the World Health Organization
(WHO) classification of nephritis [21] and scored for
activity and chronicity indices [22]. WHO class I or II
at follow-up was regarded as good histopathological re-
sponse whereas WHO III-IV and V as non-response.
As control, renal tissue from an unaffected part of a kid-
ney nephrectomised due to renal carcinoma was used.
Evaluation of renal disease activity was estimated
using the British Isles Lupus Assessment Group (BILAG)
index [23]. Renal disease activity according to BILAG is
defined as A, B, C or D according to levels of protein-
uria, creatinine and blood pressure and also based upon
findings on urinary sediment and histological data (as
defined in [23]). An improvement of at least two grades
in the renal domain of BILAG (i.e. from A to C or B to
D) at follow-up was regarded as complete response
(CR), whereas an improvement of one grade was
regarded as partial response (PR) and no improvement
as non-response (NR).
Serology and complement measures
Assessments of serum IgG anti-dsDNA antibodies were
carried out by immunofluorescence microscopy using
Crithidiae luciliae as source of antigen. Analyses of
complement component C3 (normal range 0.67-1.43 g/l)
and C4 (normal range 0.12-0.32 g/l) levels were deter-
mined by nephelometry.
Cytokine analyses
All serum samples for cytokine measurements were kept
at −70°C until use. TNF-α, IFN-γ, IL-6 and IL-10 were
measured using the Cytometric Bead Array (CBA), (BD
Biosciences Pharmingen, USA) technique. Briefly, the
standards and samples were mixed with phycoerythrin-
labeled beads and incubated for 3 h. After incubation,
the samples and standards were washed to remove un-
bound material and analyzed using the BD/CBA software.
After discussions with the manufacturer we extended the
standard curve by diluting the standard further than indi-
cated in the protocol. Hereby, the detection limits of our
assay were: IL-6 (1.0 pg/ml), IL-10 (1.5 pg/ml), IFN-γ
(4.1 pg/ml) and TNF-α (1.5 pg/ml).
IL-17, IL-23 and TGF-β were measured with ELISA
(R&D Systems, Abingdon, UK). We extended the stand-
ard curve for IL-17 and IL-23 further than indicated in
the protocol. The detection limits were 6.6 and 1.3 pg/
ml respectively.
For statistical reasons, all undetectable levels were set
to half of the detection level.
Immunostaining of renal biopsies
Immunohistochemical stainings of IL-17 expression was
performed on formaldehyde-fixed paraffin-embedded serial
4 μm sections of 6 renal biopsies from patients with LN
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xylene and rehydrated to water with ethanol. Antigen re-
trieval was achieved by microwave irradiation prior to
staining. Briefly, tween20 was used to permeabilize the
cells, endogenous peroxidase was blocked with H2O2,
avidin-biotin blocking (DAKO, Glostrup Denmark) was
used, and unspecific antibody staining was blocked using
skim milk, Poly-L-Lysine (Sigma-Aldrich, St Louis, MO,
USA) donkey and human serum. Antibodies used were
mouse anti-IL17 (R&D Systems, Minneapolis, MN, USA),
rabbit anti-CD3 (Thermo Scientific, Rockford, IL,
USA) and isotype controls, mouse IgG1 (R&D Systems,
Minneapolis, MN, USA) and rabbit (DA1E) mAb IgG
XP® Isotype Control (Cell Signaling Technology, Inc.,
Boston, MA, USA). Biotin-labelled donkey anti-rabbit-
and donkey anti-mouse secondary antibody (Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA,
USA) were used for detection. For signal amplification
Peroxidase conjugated Avidin Biotin Complex (Vector
Laboratories Inc., Burlingame, CA, USA) was used in
combination with Biotin conjugated Tyramide (TSA in-
direct blot), (PerkinElmer, Inc., Waltham, MA, USA).
Stainings were developed using DAB (Sigma-Aldrich) dis-
solved in trisbuffer saline. Sections were counterstained
with Mayer’s hematoxylin.
Statistics
For comparisons of variables at baseline and follow-up
the nonparametric Wilcoxon matched pair test was
used. For comparisons of variables between two groups
the non-parametric Mann–Whitney test was used and
for comparisons between multiple groups the Kruskal-
Wallis test was used. Correlations were calculated using
Spearman’s rank correlation. Statistical significance was
set at the level of p < 0.05. Statistical evaluation was
made by statistical software, STATISTICA 9, StatSoft,
Tulsa, USA.
Results
Renal activity and histopathology
All patients had an active nephritis at baseline with bi-
opsies showing WHO class III (n = 15), III/V (n = 4), IV
(n = 24), V (n = 8) and one glomerular vasculitis. All pa-
tients had high renal disease activity, 49/52 had renal
BILAG A and 3/52 BILAG B. Forty-six of the patients
were female (88%) and 6 were men (12%), mean age
was 32 years (range 18–59).
The patients were treated in accordance with standard
therapy for LN; corticosteroids combined with intraven-
ous cyclophosphamide (n = 40), mycophenolate mofetil
(n = 9) or rituximab (n = 2). One patient was treated with
azathioprin. The treatment regimen for cyclophospha-
mide was 0.5-1 g/m2 monthly as modified from the
NIH-protocol [24]. At the time for the first renal biopsy,36/52 (69%) of the patients were treated with prednisol-
one, median dose 20 mg/day (range 2.5-60). At start of
immunosuppressive therapy, all but one (98%) were
treated with prednisolone with median dose 40 mg/day,
doses ranging from 2.5 to 80 mg/day as decided by the
treating physician, and were thereafter successively ta-
pered. At repeat biopsies, 98% of the patients were still
treated with prednisolone, median dose 10 mg/day
(range 2.5-30).
Follow-up biopsies showed WHO class I (n = 1), II
(n = 18), III (n = 9), III/V (n = 1), IV (n = 8) and V (n =
14) and one had developed a renal vasculitis (seen in a
patient with class III at first biopsy). The patient with a
vasculitis pattern at first biopsy had class II at repeat bi-
opsy. Nineteen patients (36%) were regarded histo-
pathological responders (class I/II). The renal activity
index decreased significantly (<0.001) whereas there
was an increase in the chronicity index (p < 0.001).
Levels of C3 and C4 increased (p < 0.001) and there was
a decrease in proteinuria at follow-up (p < 0.001) whereas
no overall difference in creatinine levels was found.
At follow-up, 8/52 had renal BILAG A, 21/52 BILAG B,
11/52 BILAG C and 12/52 had BILAG D. Twenty-two pa-
tients (42.3%) were regarded as CR, 20/52 (38.5%) as PR
and 10/52 (19.2%) were regarded NR according to
BILAG. The clinical characteristics of patients and
nephritis data at baseline and follow-up are presented
in Table 1.
Serum cytokines
Most baseline levels of cytokines were increased in pa-
tients vs. controls, this was highly significant for IL-6,
IL-10, IL-17, IL-23 (p < 0.001 for all) and also significant
for IFN-γ (p = 0.03). TGF-β was lower in patients vs.
controls (p < 0.001).
Overall cytokine levels decreased after treatment, this
was significant for IL-6 (p < 0.001), IL-10 (p = 0.02) and
IL-17 (p = 0.01), for IL-23 there was a trend towards
lower levels at follow-up (p = 0.06). For TNF-α and IFN-
γ there was an overall decrease in serum levels although
not statistically significant (ns), while for TGF-β an in-
crease was documented (p = 0.005). No difference in
cytokine levels was found comparing the different im-
munosuppressive treatments or doses of prednisolone at
first and repeated biopsies (data not shown). Cytokine
levels in patients and controls are presented in Table 2.
Cytokines in association to laboratory findings
At baseline there was no correlation between proteinuria
and levels of any of the cytokines whereas at follow-up,
a positive correlation was documented for IL-23 and
proteinuria (r = 0.34, p < 0.05). Patients with persisting
urine-albumin excretion > 0.5 grams/day at follow-up
had higher IL-23 as compared to patients with <0.5
Table 1 Patient characteristics at baseline and follow-up
Baseline Follow-up p-value
Creatinine, μmol/l, median 82 (52–284) 77 (48–306) ns
Proteinuria, g/d, median 1.45 (0–8.4) 0.5 (0–3.6) <0.001
C3, g/l, median 0.5 (0.12-1.13) 0.74 (0.36-1.41) <0.001
C4, g/l, median 0.11 (0.02-0.51) 0.13 (0.02-0.45) 0.002
Anti-DNA-ab positivity#, % 84 57







Activity index, median 5 (0–13) 2 (0–12) <0.001












Range are given in parenthesis, #Anti-dsDNA raised to at least 1:25, †BILAG,
British Isles Lupus Assessment Group.
Table 2 Baseline levels of cytokines in patients at baseline vs
Patients, baseline median (range) Patients, fo
IL-6, pg/ml 10.02 (0.62-81.78)
3.29 (0.62-30
IL-10, pg/ml 9.78 (0.54-81.04)
4.95 (0.54-37
TNF-α, pg/ml 1.24 (0.55-12.51)
1.00 (0.55-78
IFN-γ, pg/ml 7.05 (0.52-338.9)
6.63 (0.52-27
IL-17, pg/ml 97.42 (3.30-381.6)
47.98 (3.30-8
IL-23, pg/ml 5.52 (0.66-121.5)
3.27 (0.66-32
TGF-β, ng/ml 42.99 (10.22-85.94)
49.46 (25.04
Values are given as medians (range).
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group of patients with very low-grade proteinuria at
follow-up (urine albumin <0.2 g/day), had more signifi-
cantly lower levels of IL-23 (p = 0.01) compared to pa-
tients with ≥ 0.2 g/day.
A weak inverse correlation was documented at baseline
for C3 and IL-10 (r = −0.31, p < 0.05) and at follow up for
C3 and IL-23 (r = −0.44, p < 0.05), TNF-α (r = −0.36,
p < 0.05) and IFN-γ (r = −0.30, p < 0.05) whereas no cor-
relations were found for C4.
There was no correlation between serum creatinine
and any of the investigated cytokines.
Cytokines in association to histopathology
First we studied the cytokines in association to histopatho-
logical findings at both first and repeated biopsies. There
was no difference in baseline cytokine levels between pa-
tients with class III, IV (proliferative nephritis, PN) vs.
class V (membranous nephritis, MN) at baseline biopsies.
Patients with a poor histopathological response, i.e.
with a persisting active nephritis after immunosuppres-
sive treatment, had significantly higher baseline levels of
IL-17 compared to patients with WHO I or II at follow-
up (median 111.0 vs. median 53.1 pg/ml) (p = 0.03)
(Figure 1a). The highest baseline levels of IL-17 were
seen in patients with MN at repeat biopsy (median
146.5 pg/ml) (Figure 1b). No significant differences in
baseline levels of any of the other cytokines were found be-
tween histopathological responders and non-responders.
Patients displayed higher IL-17 both at baseline (p <
0.001) and follow-up (p = 0.01) compared to controls
(Figure 2a). Patients with the highest levels of IL-17 at
baseline (arbitrarily defined as >165 pg/ml and encom-
passing the upper quartile), also had higher levels of IL-. controls, and baseline vs. follow-up levels in patients















Figure 1 Baseline levels of IL-17 were higher in patients with an unfavourable histopathological outcome. (a) Baseline levels were significantly
higher in patients who had a persisting active nephritis (WHO class III, IV or V) at follow-up, i.e. WHO non-responders, vs.WHO responders (WHO I or II).
(b) Baseline levels of IL-17 in patients in relation to histopathology at follow-up. The patient with vasculitis at repeat biopsy was here included in the class
III-IV group. The highest levels were seen in patients with a memranous nephritis, WHO class V, at follow-up. Boxes limits show 25th to 75th percentile and
median values are marked inside the boxes.
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those with IL-17 levels <165 pg/ml (Figure 2b, c and d).
Of these patients, 11/13 (85%) were histopathological
non-responders. At follow-up, 8/52 patients had persist-
ently high IL-17 levels as defined above (Figure 2a), this
subgroup also had higher levels of TNF-α (p = 0.0001)
and IFN-γ (p = 0.0006) (Figure 3a and b) and were all
histopathological non-responders (WHO III n = 4, WHO
V n = 3 and one with glomerular vasculitis).Cytokines in association to clinical response
We also analysed cytokine levels in association to clin-
ical response according to the definition used.
Patients displayed higher IL-23 levels compared to con-
trols both at baseline (p < 0.001) and follow-up (p < 0.001)
(Figure 4a). At follow-up, BILAG-non-responders (NR)
had significantly higher levels of IL-23 (median 10.6 pg/
ml) vs. complete responders (CR) (median 2–6 pg/ml,
p = 0.02) (Figure 4b). This was even more pronounced
in the subgroup of patients with MN at follow-up (n =
14), in which the non-responding patients had higher
IL-23 (median 10.9 pg/ml) vs. both PR (median 5.0 pg/
ml, p = 0.05) and CR (median 1.2 pg/ml, p = 0.01)
(Figure 4c).
No significant difference between CR-, PR- and NR-
patients was found for any of the other cytokines.Correlations between cytokines
At baseline, IL-17 correlated with TNF-α (r = 0.63, p <
0.05), IFN-γ (r = 0.49, p < 0.05) and IL-23 (r = 0.30, p <0.05). There was also a correlation between TNF-α and
IFN-γ (r = 0.71, p < 0.05).
At follow up, IL-17 correlated with IFN-γ (r = 0.80, p <
0.05) and TNF-α (r = 0.79, p < 0.05). There was also a cor-
relation between TNF-α and IFN-γ (r = 0.80, p < 0.05).Immunohistochemistry
Immunostaining demonstrated expression of IL-17 in all
the 6 examined biopsies from LN patients (4 with class
V and 2 with class IV). The staining was most pro-
nounced in areas of inflammatory infiltrates of CD3+ T-
cells (Figure 5). There was no clear difference observed
in the amount of IL-17 comparing PN and MN. In renal
tissue from control kidney biopsies, IL-17 staining was
negative (data not shown).Discussion
High baseline levels of IL-17 were here demonstrated as
a marker of inadequate histopathological outcome after
immunosuppressive therapy in LN, indicating that high
IL-17 production could be associated with a severe, or
therapy resistant, disease phenotype. Furthermore, high
levels of IL-23 were associated with a poor clinical out-
come. Our findings thus extend previous studies of an
important role for the IL-23/IL-17 axis in LN, here also
demonstrated to associate with therapeutic outcome.
Our study also confirms and strengthens previous re-
ports on increased levels of IL-6, IL-10, TNF-α, IFN-γ,
IL-17 and IL-23 as well as low TGF-β in lupus patients
[6,25-27].
Figure 2 Serum levels of IL-17 in patients and controls. Patients with the highest baseline levels had higher levels of IL-23, TNF-α and IFN-γ.
(a) Serum levels of IL-17 in patients at baseline and follow-up in patients and levels in controls (medians 97.4, 48.0 and 3.3 pg/ml respectively). The dotted
line denotes the upper 25% of IL-17 levels (above 165 pg/ml). The patients with the highest baseline levels of IL-17 (>165) pg/ml had higher levels of
IL-23 as shown in (b), TNF-α (c) and IFN-γ (d) vs. those with IL-17 levels < 165. Boxes limits show 25th to 75th percentile and median values are marked
inside the boxes.
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the pathogenesis of SLE. Previous studies have shown in-
creased number of IL-17 producing cells in peripheral
blood [13], including both CD4+ Th17-cells and DN T-
cells [16], and increased serum levels of IL-17 in SLE pa-
tients [12]. In LN, DN T-cells have been proposed to be
the major source for IL-17, supported by studies demon-
strating that DN T-cells infiltrate the kidneys of LN pa-
tients and produce high amounts of IL-17 and IFN-γ
[16]. Similar findings have also been shown in experi-
mental studies, demonstrating DN T-cells in inflamma-
tory infiltrates and increased IL-17 and IFN-γ in kidneys
in murine lupus models [28]. Our findings of high levels
of IL-17, in combination with elevated IFN-γ, in patientswith an unfavourable histopathological outcome, provide
a context to previous observations.
Immunostaining revealed IL-17 expression in renal tis-
sue from LN patients, most pronounced in areas with
infiltrating T-cells, this confirms previous findings and
clearly indicates that IL-17 is involved in the inflamma-
tory process in the renal tissue.
High baseline IL-17 was associated with a poor histo-
pathological response, with significantly higher levels
among non-responder patients. Interestingly, the sub-
group of patients with high baseline levels in combin-
ation with persistently high or increasing levels, all had
an active nephritis at follow-up. Although this group
only consisted of eight patients, this indicates that
Figure 3 Patients with persisting high levels of IL-17 at follow-up had higher levels of TNF-α and IFN-γ. Patients with persisting high levels of
IL-17 (>165 pg/ml) had significantly higer levels of TNF-α (a) and IFN-γ (b) vs those with IL-17 < 165 pg/ml. Boxes limits show 25th to 75th percentile
and median values are marked inside the boxes.
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LN with a strong T-cell component in whom current
treatments may be insufficient or inadequate. This noti-
fication is further emphasized by the observation that
the patients with the highest baseline IL-17 also had
higher TNF-α, IFN-γ and IL-23, and of whom a majority
was non-responsive to treatment.
High IL-23 levels were shown to be associated with
poor clinical response as estimated by BILAG. Interest-
ingly, patients with MN at follow-up had the highest
levels of IL-17. In addition, among clinical NR-patients,
the highest levels of IL-23 were seen in MN. TakenFigure 4 Follow-up levels of IL-23 were higher in patients with an un
baseline and follow-up in patients and levels in controls (medians 5.5, 3.3 a
significantly higher in BILAG non-responder (NR) patients vs. partial- (PR) and
patients with WHO class V at follow-up as shown in (c). Boxes limits show 25ttogether, the findings may indicate a particular role for
IL-23/IL-17 in MN but warrant further studies in larger
patient populations.
As biomarkers currently available for assessing renal
activity or response to therapy do not always reflect the
actual inflammatory activity in renal tissue [29-31] there
is a clear need for novel tools to assess activity in LN.
Although new biomarkers both in blood and urine, in-
cluding several cytokines, have been studied in LN, none
have yet replaced conventional clinical parameters to
monitor renal disease activity in clinical practise. It has
also been proposed that a combination of biomarkersfavourable BILAG response. (a) Serum levels of IL-23 in patients at
nd 0.7 pg/ml respectively). (b) Levels of of IL-23 in all patients were
complete responders (CR), this was most pronounced in the group of
h to 75th percentile and median values are marked inside the boxes.
Figure 5 Immunostaining of IL-17 in renal tissue. The figure demonstrates a kidney biopsy from a patient with lupus nephritis WHO class V.
Representative micrographs displaying (A) an inflammatory infiltrate with T cells as demonstrated by a positive CD3-staining and in (B) the same
infiltrate from a consecutive section stained with irrelevant isotype control antibody. In (C), IL-17 staining is demonstrated, predominantly found
in the inflammatory infiltrate shown in A, and (D) demonstrates staining with the corresponding isotype control antibody. Original
magnifications: 12.5×.
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tivity [32-34]. Our findings of high IL-17 and IL-23 in
relation to treatment outcome in LN suggest that these
cytokines could be evaluated as novel biomarkers for se-
vere disease.
Evaluation of response in LN is difficult, and despite ex-
tensive efforts, there are currently no generally accepted
response criteria available. Most studies in LN use pro-
teinuria as the most important outcome for response, here
we used response according to change in renal BILAG
which include change in proteinuria. Recently a consensus
statement on the terminology used in LN was published,
also proposing that the term remission should only be
used based upon findings on a renal biopsy [35]. Having
repeated biopsies available, we evaluated both clinical and
histopathological response, thus giving unique opportun-
ities to define response on a tissue level.
Introduction of new treatment strategies and improved
global care have improved the prognosis in LN. However,
a proportion of patients do not respond satisfactory to
standard immunosuppressive treatment. Side effects of
currently used therapies are a concern and long-term out-
come remains unsatisfactory [36,37]. Accordingly, there is
definitely a need for improved and more targeted treat-
ment strategies in LN. Increased knowledge about the
pathogenesis for SLE, in combination with the successful
use of biologics in other autoimmune diseases, have paved
the way for the development of biologic agents targetingdifferent cytokine pathways also in SLE and thus, many
anti-cytokine therapies for SLE are currently studied [38].
Trials targeting the IL-23/IL-17 pathway are underway for
various autoimmune diseases, and targeting IL-23 (p40) is
already in use for psoriasis, but the efficacy of these ther-
apies in lupus remains to be studied [5]. Interestingly, a re-
cent report documented beneficial effects of treatment of
subacute cutaneous lupus with ustekinumab, a human
monoclonal antibody that binds to the p40 subunit of IL-
23 and inhibits its biological effects [39], indicating that
blocking of IL-23 may be useful in lupus patients.
The main focus of the study has been lupus nephritis
where non-renal manifestations have not been taken
into consideration but may, at least to some extent,
have influenced the cytokine levels. However, the in-
creased IL-17 staining in the renal biopsies clearly
points to its involvement in LN. Differences in treat-
ment regimens may also have impact on study results.
In this study most patients received high-dose CYC,
however nowadays the low-dose Euro-lupus regimen
[40] is standard of care for LN. There were no differ-
ences in cytokine levels comparing MMF and CYC, but
whether different dose regimens of CYC may have im-
pact on cytokine levels are not known.
Conclusions
This study clearly supports a role for IL-23/IL-17 axis in
LN and indicates that this cytokine pathway can be useful
Zickert et al. BMC Immunology  (2015) 16:7 Page 9 of 10as biomarkers for renal disease activity and for predicting
response to immunosuppressive treatment, especially in
patients with a membranous phenotype. If monitoring of
IL-17/ IL-23 could be helpful in predicting renal flares or
could be used as predictors of long-term prognosis needs
to be further studied. The findings may also point to pos-
sible targets for new treatment strategies in LN.
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